PROCEPT BioRobotics to report Q2 2026 results on August 4

1 min read Updated on 15 Jul 2026, 03:50 AM

Reviewed by

Jubin VScanX News Team

AI Summary

PROCEPT BioRobotics Corporation will announce its financial results for the second quarter of 2026 after market close on August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. The webcast and replay will be available on the company's website.

*this image is generated using AI for illustrative purposes only.

PROCEPT BioRobotics Corporation will announce its financial results for the second quarter of 2026 after market close on August 4, 2026. The company's management will host a conference call at 4:30 p.m. Eastern Time to discuss the performance. Investors can access the live webcast via the "Investors" section of the PROCEPT BioRobotics website. An archived recording will be available for replay for at least 90 days following the event.

Conference Call Details

Event	Details
Date	August 4, 2026
Time	4:30 p.m. Eastern Time
Webcast Link	https://edge.media-server.com/mmc/p/8fznodv2
Analyst Registration	https://register-conf.media-server.com/register/BI52750114763b4e46862d9605fe2f2b01

About PROCEPT BioRobotics

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The company is also pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies.

What key metrics should investors focus on during the Q2 2026 earnings call to gauge the adoption rate of the HYDROS Robotic System?

How might PROCEPT's clinical research initiatives in prostate cancer impact its long-term growth strategy beyond BPH treatment?

What competitive challenges could PROCEPT face in the surgical robotics market, and how might it differentiate itself?

Read Next Article

Truist downgrades PROCEPT BioRobotics to Hold, cuts target to $25

0 min read Updated on 06 Jul 2026, 06:38 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

Truist Securities analyst Richard Newitter downgraded PROCEPT BioRobotics from Buy to Hold and lowered the price target to $25 from $30.

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Richard Newitter has downgraded PROCEPT BioRobotics from Buy to Hold. The firm also reduced the price target for the stock to $25 from the previous $30. PROCEPT BioRobotics is listed on NASDAQ under the ticker PRCT.

What specific factors led Truist Securities to downgrade PROCEPT BioRobotics from Buy to Hold?

How might the reduced price target affect investor sentiment toward PROCEPT BioRobotics in the short term?

What are the potential risks or challenges facing PROCEPT BioRobotics that could impact its future performance?